The role of HMGB2 on prostate cancer progression and castration resistance

2017 Fiscal Year Final Research Report

• Project/Area Number: 15K08352
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Human pathology
• Research Institution: Nagoya City University
• Principal Investigator: Suzuki Shugo 名古屋市立大学, 大学院医学研究科, 講師 (60363933)
• Co-Investigator(Kenkyū-buntansha): 佐藤 慎哉 名古屋市立大学, 大学院医学研究科, 研究員 (30464564) ; 内木 拓 名古屋市立大学, 大学院医学研究科, 講師 (50551272) ; 高橋 智 名古屋市立大学, 大学院医学研究科, 教授 (60254281)
• Project Period (FY): 2015-04-01 – 2018-03-31
• Keywords: Prostate cancer / HMGB2 / progression / cell proliferation / androgen receptor

Outline of Final Research Achievements

High mobility group box 2 (HMGB2), which belongs the HMG protein families, was up-regulated in prostate adenocarcinoma compared to normal epithelium. In this study, we investigated functions of HMGB2 for progression, androgen regulation and cell proliferation of hormone naive and castration resistant prostate cancer.
In prostatectomy samples, HMGB2 expression was correlated with Gleason grading and tumor stage, but was not related with overall survival. Compared to hormone naive prostate cancer, HMGB2 expression in hormone-treated prostate cancer tended to be decreased, and was reverse correlated with therapeutic effect.
In prostate cancer cell lines, HMGB2 regulated androgen receptor-mediated pathway in androgen dependent cell line, LNCaP. HMGB2 also regulated cell proliferation in both androgen dependent and independent cancer cell lines.

Free Research Field

病理学